Summary
A 12-week double-blind randomized drug trial followed by an open extension period of 36 weeks was carried out in 38 male patients with ankylosing spondylitis (AS) to compare the efficacy and safety of diflunisal (500 mg twice daily) and phenylbutazone (200 mg twice daily). Both drugs proved to be effective in improving the severity of symptoms associated with AS, and this improvement was maintained throughout the open extension period. Initially diflunisal had a more pronounced and rapid analgesic action, whereas phenylbutazone was more effective in increasing axial mobility. During the study 9 patients dropped out: 3 in each treatment group due to side effects and 1 in each group due to lack of efficacy; another patient was lost to follow-up. The two drugs were similarly safe as judged by the occurrence of adverse clinical effects, mainly gastrointestinal. This study again demonstrates the value of phenylbutazone in AS but, taking into account the possible haematological side effects, the use of other NSAIDs is stressed. Diflunisal is an alternative capable of improving the painful stiffness associated with AS.
Similar content being viewed by others
References
Boersma, J.W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976, 5, 60–6.
Vthovac, B. Phenylbutazon and related compounds. In: Meyler's Side Effects of Drugs, 10th ed. Editor: Dukes M.N.G. Amsterdam, Elsevier 1984, 153–6.
Calabro, J.J., Amante, C.M. Indomethacin in ankylosing spondylitis. Arthritis Rheum, 1968, 11, 56–64.
Hill, H.E.H., Hill, A.G.D. Ankylosing spondylitis: open long-term and double-blind crossover studies with naproxen. J Clin Pharmacol, 1975, 15, 355–62.
Ansell, B.M., Mayor, G., Liyanage et al. A comparative study of butacote and naprosyn in ankylosing spondylitis. Ann Rheum Dis, 1978, 37, 436–9.
Godfrey, R.G., Calabro, J.J., Mills, D. et al. A double-blind crossover trial of aspirin, indomethacin and phenylbutazone in ankylosing spondylitis. Arthritis Rheum, 1972, 15, 110 (abstract).
Brogden, R.N., Heel, R.C., Pakes, G.E. et al. Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and strains and pain in osteoarthritis. Drugs, 1980, 19, 84–106.
Brooks, P.M., Dougan, M.A., Thomas, D., Hills, L.J., Smith, P.J. Naproxen and diflunisal in osteoarthritis. Rheumatol Rehabil, 1982, 21, 95–97.
Huskisson, E.C., Dieppe, P.A., Scott, I., Jones, H. Diclofenac sodium, diflunisal and naproxen: patient preferences for anti-inflammatory drugs in rheumatoid arthritis. Rheumatol Rehabil, 1982, 21, 238–242.
Van Loenhout, J.W.A., van de Putte, L.B.A., Gribnau, F.W.J., MacRae, K.D., Van Ginneken, C.A.M. Long-term clinical trial with naproxen sodium versus diflunisal in rheumatoid arthritis. M.D. thesis 1981, Nijmegen, pp. 43–60.
Ferraccioli, G., Spisni, A., Ambarelli, K. Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. J Rheumatol, 1984, 11, 330–332.
Bennet, P.H.J., Burch, T.A. Population studies of the rheumatic diseases. Amsterdam, Excerpta Medica Foundation 1968, pp 456–457.
Steinbrocker, O., Traeger, C.H., Batterman, R.C. Ara functional class. JAMA, 1949, 140, 659–65.
Moll, J.H.M., Wright, V. An objective clinical study of chest expansion. Ann Rheum Dis, 1972, 31, 1–8.
Van Adrichem, J.A.M., Van der Korst, J.K. Assessment of the flexibility of the lumbar spine. Scand J Rheumatol, 1973, 2, 87–91.
Quanjer, Ph.H., Dalhuysen, A., van Zomeren, B.C. Summary equations of reference values. In: Clin Resp Phys. Editor P.M. Quanjer, 1985, 19, (suppl 5), 49.
Forbes, J.A., Beaver, W.T., White, E.H., White, R.W., Neilson, G.B., Shackleford, R.W. Diflunisal — a new oral analgesic with an unusually long term duration of action. JAMA, 1982, 248, 2139–2142.
Josenhans, W.T., Wang, C.S., Josenhans, C., Woodbury, J.F.C. Diaphragmatic contribution to ventilation in patients with ankylosing spondylitis. Respiration, 1971, 28, 331–346.
Wasner, C., Britton, M.C., Kraines, R.G., Kaye, R.C., Bobrore, A.M., Fries, J.F. Non-steroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA, 1981, 246, 2168–2172.
Rheinberger, K. Efficacy and tolerance of diclofenac and indomethacin in patients with ankylosing spondylitis. Therapiewoche, 1976, 26, 2916–2920.
Calin, A., Grahame, R. Double-blind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J, 1974, 4, 496–499.
Romberg, O. Comparison of piroxicam with indomethacin in ankylosing spondylitis. A double-blind cross-over trial. Am J Med, 1982, 73 (suppl), 58–62.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Franssen, M.J.A.M., Gribnau, F.W.J. & Van De Putte, L.B.A. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin Rheumatol 5, 210–220 (1986). https://doi.org/10.1007/BF02032359
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02032359